AI CuratorAI-generated
Research summary · AI summary · not yet reviewedHuman studyPhase 2Trial registry
Fenebrutinib in Human Relapsing Multiple Sclerosis
A Phase 2 trial involving 109 patients with relapsing multiple sclerosis tested fenebrutinib (200 mg, BID) against a placebo. Results showed a significant reduction in Gd-enhancing T1 lesions on MRI scans (0.077 lesions vs. 0.245 lesions per scan, p=0.0022).
- Tags
- #MSResearch
- Most relevant to
- —
- Source
- Read original source
This plain-English summary was written by AI from a published abstract and may contain errors. It is not medical advice. Read the original study and talk to your MS team before making decisions about treatment.
Why it matters
These findings suggest that fenebrutinib may help decrease lesion load in relapsing multiple sclerosis, which is significant for understanding potential treatment options.
What this does not prove
The trial is ongoing, and participant flow and study details may change as more data is collected.
Next milestone
No next milestone was established from the available source.
Study facts
- Study design
- Interventional
- Participants / samples
- 109 · basis not reported
- Randomised
- Yes
- Controlled
- Yes
- Primary endpoint met
- Yes
- Relevant MS type
- RRMS
- Publication date
- Not reported
- Evidence reviewed
- Trial registry record
- Regulatory approval
- Yes
- Research areas
- Not classified
Original sources
Supporting passages (15)
study phase"phases": [ "PHASE2" ]
study design"studyType": "INTERVENTIONAL"
subjects"populationDescription": "All Randomized Participants set included all randomized participants grouped by treatment as assigned by randomization."
sample size"count": 109, "type": "ACTUAL"
randomized"allocation": "RANDOMIZED"
controlled"type": "PLACEBO_COMPARATOR"
primary endpoint met"reportingStatus": "POSTED"
regulatory approval"isFdaRegulatedDrug": true
regulatory approval details"isFdaRegulatedDrug": true
relevant ms types"conditions": [ "Relapsing Multiple Sclerosis" ]
intervention"Participants will receive oral fenebrutinib."
comparator"Participants will receive oral placebo."
primary endpoint"measure": "DBT Phase: New Gadolinium (Gd) - Enhancing T1 Lesion Rate Observed on Magnetic Resonance Imaging (MRI) Scans of the Brain Over 12 Weeks"
findings"value": "0.077"
limitationsThis study is still ongoing.",
AI assessment, not yet reviewed by a person · version 1 · Community votes are separate from evidence review.